Mankind Pharma Q3FY26 Results: Standalone Profit at ₹449.47 Crore
Mankind Pharma reported unaudited standalone results for Q3FY26. Revenue from operations reached ₹2,632.68 crore, with a profit after tax of ₹449.47 crore. For the nine months ended December 31, 2025, revenue was ₹7,839.36 crore and profit after tax was ₹1,329.04 crore. Key ratios include a debt-equity ratio of 0.40 and a net profit margin of 17%.
The announcement includes financial results, which are material information for investors. While the results are positive, they do not indicate a significant strategic shift or a major event that would warrant a 'HIGH' impact rating.
The company reported profitable results for the quarter and nine months ended December 31, 2025, with positive revenue growth and a healthy profit after tax. The auditors provided an unmodified conclusion, indicating no significant concerns.
Mankind Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 3, 2026, which commenced at 3:00 p.m. IST and concluded at 3:45 p.m. IST.
For the quarter ended December 31, 2025, the company reported standalone revenue from operations of ₹2,632.68 crore and a profit after tax of ₹449.47 crore. Total comprehensive income for the quarter stood at ₹452.53 crore. The basic earnings per share (EPS) from continuing operations were ₹10.89.
For the nine months ended December 31, 2025, standalone revenue from operations was ₹7,839.36 crore, with a profit after tax of ₹1,329.04 crore. Total comprehensive income for the period was ₹1,349.21 crore. The basic EPS from continuing operations for this period was ₹32.20.
The company also provided additional disclosures as per Regulation 52(4) and 54(3) of SEBI Listing Regulations. Key ratios include a debt-equity ratio of 0.40 for the quarter, a net worth of ₹15,734.34 crore, an operating margin of 26%, and a net profit margin of 17% for the quarter ended December 31, 2025.
The auditors, M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., issued an unmodified conclusion on the unaudited standalone and consolidated financial results. Explanatory notes detailed adjustments for business combinations, amalgamation schemes, and the transfer of the OTC business. Exceptional items of ₹83.42 crore were noted for the quarter, comprising impacts from new labor codes and stamp duty related to an IP assignment.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.